Table 1 Summary of treatment strategies, peri-partum management and anti-Xa monitoring used by respondents
From: Management of pregnancy associated venous-thromboembolism: a survey of practices
LMWH Full dose BID | LMWH Full dose OD | UFH IV | UFH SC BID | LMWH intermediate dose OD | Other | ||
|---|---|---|---|---|---|---|---|
% (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | ||
Acute treatment | DVT | 62.3 (50–73) | 36.2 (25–48) | 0 | 1.4 (0–7) | NA | 0.14 (0–7) |
PE | 62.3 (50–73) | 29 (19–40) | 5.8 (2–13) | 1.4 (0–7) | NA | 1.4 (0–7) | |
Long-term treatment | DVT | 36.2 (25–48) | 34.8 (24–46) | NA | 0 | 23.2 (14–34) | 5.8 (2–13) |
PE | 37.7 (26–49) | 36.2 (25–48) | NA | 0 | 21.7 (13–32) | 4.4 (1–11) | |
Weekly | Once a month | Weekly in special populations* | Once a month in special populations* | Never | Other | ||
% (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | ||
Anti-Xa monitoring | Acute treatment | 20. 4 (12–31) | 26 (16–37) | 7.2 (3–15) | 15.9 (9–26) | 20.4 (12–31) | 10.1 (4–19) |
Long-term | 1.4 (0–7) | 17.4 (10–27) | 2.9 (0–9.2) | 30.4 (20–42) | 34.8 (24–46) | 13.1 (24–46) | |
Treatment | |||||||
IVC filter + LMWH BID | IVC filter + IV UFH | LMWH BID | UFH SC BID | UFH IV | Other | ||
% (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % | ||
Peri-partum Management | VTE > 4 weeks | 0 | 0 | 53.6 (41–65) | 18.8 (11–29) | 5.8 (2–13) | 21.7 (0–9.2) |
VTE <4 and >2 weeks | 0 | 2.9 (0–9.2) | 31.9 (21–43) | 10.1 (4–19) | 39.1 | 11.7 (5–20) | |
VTE <2 weeks | 21.7 (15–32) | 29 (19–40) | 10.1 (4–19) | 2.9 (0–9.2) | 13.1 (6–22) | 20.4 (12–31) |